Skip to main content
logo
Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.120
+0.020 (0.95%)
Sep 8, 2026, 4:00 PM EDT - Market closed

Grace Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Apr - Mar.

Total Valuation

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Market Capitalization
457231322154
Market Cap Growth
8.51%129.06%-2.84%56.90%-62.03%-55.00%
Enterprise Value
3153207-108
Last Close Price
2.124.632.283.422.767.32

Price Ratios

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PB Ratio
0.721.120.470.520.300.50
P/TBV Ratio
3.574.901.812.581.102.12

Financial Efficiency

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Debt / Equity Ratio
----0.010.00
Net Debt / Equity Ratio
-0.28-0.27-0.33-0.37-0.40-0.40
Net Debt / EBITDA Ratio
1.331.531.332.041.523.87
Net Debt / FCF Ratio
1.341.911.491.861.722.52
Quick Ratio
11.027.9211.5314.098.4113.56
Current Ratio
11.478.1011.7714.268.5913.89
Return on Equity (ROE)
-36.19%-11.94%-14.91%-19.82%-48.15%-11.98%
Return on Assets (ROA)
-10.81%-9.99%-14.35%-9.25%-10.96%-7.94%
Return on Capital Employed (ROCE)
-21.20%-17.20%-23.80%-15.70%-24.00%-9.70%

Yields

Fiscal Year
CurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Earnings Yield
-45.34%-10.88%-30.59%-39.92%-206.80%-18.17%
FCF Yield
-23.07%-12.38%-47.65%-38.38%-77.64%-31.90%
Buyback Yield / Dilution
-26.32%-36.59%-26.85%-28.16%-21.09%-148.46%
SEC Filings: 10-K · 10-Q